SOURCE: StockCall

StockCall

June 23, 2011 08:32 ET

Analyst Research on Pharmaceutical Product Development Inc. and Covance Inc. -- Medical Laboratories Improving

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Jun 23, 2011) - www.stockcall.com/ offers investors comprehensive research on the Medical Laboratories & Research industry and has completed analytical research on Pharmaceutical Product Development Inc. (NASDAQ: PPDI) and Covance Inc. (NYSE: CVD). Register with us today at www.stockcall.com/ to have free access to these researches.

The medical laboratories and research industry is having a strong 2011 with the help of a better economy, improved spending from big pharma and backlogged trials. Acquisitions of smaller companies that struggled during the recession are also beginning to pay off. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the Medical Laboratories & Research industry.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the Medical Laboratories & Research industry can have easy and free access to our analyst research and opinions on Pharmaceutical Product Development Inc. and Covance Inc.; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

Laboratories that saw revenue drops during the recession are benefitting from trials that were backlogged by medical companies cutting costs. Both Pharmaceutical Product Development Inc. and Covance Inc. are in a good position to absorb any contract cancellations because of strong backlogs. Investors looking for free research on Pharmaceutical Product Development Inc. are welcome to sign up at www.stockcall.com/PPDI230611.pdf for our new report.

PPDI has $3.4 billion in backlogged authorizations. Similarly, at the completion of their latest quarter, Covance's backlog jumped 31.3% to $6.3 billion on a year over year basis. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

Overall, the medical laboratories and research industry is in a good position at the moment. Postponed trials are driving revenues for several companies. The industry will always be affected by the general state of the global economy. Regulatory changes are also a constant threat to revenues and business models. Investors looking for complimentary research on Covance Inc. are welcome to sign up at www.stockcall.com/CVD23DD0611.pdf for our new report.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information